JP2005520824A - ナノ粒子形態の２−（４−エトキシ−フェニル）−３−（４−メタンスルホニル−フェニル）−ピラゾロ［１，５−ｂ］ピリダジンを含有する医薬組成物 - Google Patents

ナノ粒子形態の２−（４−エトキシ−フェニル）−３−（４−メタンスルホニル−フェニル）−ピラゾロ［１，５−ｂ］ピリダジンを含有する医薬組成物 Download PDF

Info

Publication number
JP2005520824A
JP2005520824A JP2003575973A JP2003575973A JP2005520824A JP 2005520824 A JP2005520824 A JP 2005520824A JP 2003575973 A JP2003575973 A JP 2003575973A JP 2003575973 A JP2003575973 A JP 2003575973A JP 2005520824 A JP2005520824 A JP 2005520824A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
present
compound
weight
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003575973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520824A5 (de
Inventor
アップルビー，ジョナサン
ヒル，マーティン，ロルフ
ホランド，サイモン，ジョセフ
ピアソン，ステファニー，リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005520824A publication Critical patent/JP2005520824A/ja
Publication of JP2005520824A5 publication Critical patent/JP2005520824A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003575973A 2002-03-15 2003-03-13 ナノ粒子形態の２−（４−エトキシ−フェニル）−３−（４−メタンスルホニル−フェニル）−ピラゾロ［１，５−ｂ］ピリダジンを含有する医薬組成物 Pending JP2005520824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206200.8A GB0206200D0 (en) 2002-03-15 2002-03-15 Pharmaceutical compositions
PCT/EP2003/002698 WO2003077920A1 (en) 2002-03-15 2003-03-13 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form

Publications (2)

Publication Number Publication Date
JP2005520824A true JP2005520824A (ja) 2005-07-14
JP2005520824A5 JP2005520824A5 (de) 2006-01-05

Family

ID=9933079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575973A Pending JP2005520824A (ja) 2002-03-15 2003-03-13 ナノ粒子形態の２−（４−エトキシ−フェニル）−３−（４−メタンスルホニル−フェニル）−ピラゾロ［１，５−ｂ］ピリダジンを含有する医薬組成物

Country Status (21)

Country Link
US (1) US20050153967A1 (de)
EP (1) EP1485098B1 (de)
JP (1) JP2005520824A (de)
KR (1) KR20040091133A (de)
CN (1) CN1642549A (de)
AT (1) ATE350038T1 (de)
AU (1) AU2003208709A1 (de)
BR (1) BR0307427A (de)
CA (1) CA2478758A1 (de)
DE (1) DE60310896T2 (de)
EA (1) EA007201B1 (de)
EC (1) ECSP045295A (de)
ES (1) ES2277634T3 (de)
GB (2) GB0206200D0 (de)
IS (1) IS7378A (de)
MX (1) MXPA04009008A (de)
NO (1) NO20043889L (de)
NZ (1) NZ534179A (de)
PL (1) PL372932A1 (de)
WO (1) WO2003077920A1 (de)
ZA (1) ZA200406553B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012930A1 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2002000196A2 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012930A1 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
WO2002000196A2 (en) * 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process

Also Published As

Publication number Publication date
CA2478758A1 (en) 2003-09-25
GB0419971D0 (en) 2004-10-13
NZ534179A (en) 2006-07-28
PL372932A1 (en) 2005-08-08
GB2402335B (en) 2005-10-12
WO2003077920A1 (en) 2003-09-25
EP1485098A1 (de) 2004-12-15
AU2003208709A1 (en) 2003-09-29
IS7378A (is) 2004-07-29
EP1485098B1 (de) 2007-01-03
ZA200406553B (en) 2005-09-22
ECSP045295A (es) 2004-10-26
MXPA04009008A (es) 2004-12-07
CN1642549A (zh) 2005-07-20
KR20040091133A (ko) 2004-10-27
BR0307427A (pt) 2004-12-28
EA007201B1 (ru) 2006-08-25
NO20043889L (no) 2004-09-16
DE60310896T2 (de) 2007-05-10
GB2402335A (en) 2004-12-08
DE60310896D1 (de) 2007-02-15
US20050153967A1 (en) 2005-07-14
GB0206200D0 (en) 2002-05-01
ATE350038T1 (de) 2007-01-15
EA200400864A1 (ru) 2005-02-24
ES2277634T3 (es) 2007-07-16

Similar Documents

Publication Publication Date Title
US20200375968A1 (en) Apixaban formulations
TWI428333B (zh) 醫藥組合物
ES2366394T3 (es) Composiciones de eprosartán.
WO2009084041A2 (en) Pharmaceutical compositions of dexibuprofen
US20030022928A1 (en) Novel compositions of eprosartan
JP2005520824A (ja) ナノ粒子形態の２−（４−エトキシ−フェニル）−３−（４−メタンスルホニル−フェニル）−ピラゾロ［１，５−ｂ］ピリダジンを含有する医薬組成物
AU2017228681B2 (en) Apixaban formulations
MXPA00008888A (en) Novel compositions of eprosartan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091006